COVID-19 vaccine candidates and vaccine development platforms available worldwide

Nilgun Duman; Zahraa ALzaidi; Busra Aynekin; Duygu Taskin; Busra Demirors; Abdulbaki Yildirim; Izem Olcay Sahin; Faik Bilgili; Eda Tahir Turanli; Tommaso Beccari; Matteo Bertelli; Munis Dundar

doi:10.1016/j.jpha.2021.09.004

Volume 11 Issue 6

Dec. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2021 > 11(6): 675-682

Nilgun Duman, Zahraa ALzaidi, Busra Aynekin, Duygu Taskin, Busra Demirors, Abdulbaki Yildirim, Izem Olcay Sahin, Faik Bilgili, Eda Tahir Turanli, Tommaso Beccari, Matteo Bertelli, Munis Dundar. COVID-19 vaccine candidates and vaccine development platforms available worldwide[J]. Journal of Pharmaceutical Analysis, 2021, 11(6): 675-682. doi: 10.1016/j.jpha.2021.09.004

Citation:

Nilgun Duman, Zahraa ALzaidi, Busra Aynekin, Duygu Taskin, Busra Demirors, Abdulbaki Yildirim, Izem Olcay Sahin, Faik Bilgili, Eda Tahir Turanli, Tommaso Beccari, Matteo Bertelli, Munis Dundar. COVID-19 vaccine candidates and vaccine development platforms available worldwide[J]. Journal of Pharmaceutical Analysis, 2021, 11(6): 675-682. doi: 10.1016/j.jpha.2021.09.004

Citation:

Nilgun Duman, Zahraa ALzaidi, Busra Aynekin, Duygu Taskin, Busra Demirors, Abdulbaki Yildirim, Izem Olcay Sahin, Faik Bilgili, Eda Tahir Turanli, Tommaso Beccari, Matteo Bertelli, Munis Dundar. COVID-19 vaccine candidates and vaccine development platforms available worldwide[J]. Journal of Pharmaceutical Analysis, 2021, 11(6): 675-682. doi: 10.1016/j.jpha.2021.09.004

PDF( 1030 KB)

COVID-19 vaccine candidates and vaccine development platforms available worldwide

doi: 10.1016/j.jpha.2021.09.004

a. Department of Medical Genetics, Dragos Hospital Istanbul, Bezmialem Vakif University, Istanbul, 34854, Turkey;
b. Department of Biotechnology, Faculty of Applied Science, Cukurova University, Adana, 01380, Turkey;
c. Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey;
d. Department of Economics, Faculty of Economics and Administrative Sciences, Erciyes University, Kayseri, 38030, Turkey;
e. Department of Molecular Biology and Genetics, Faculty of Science, Acibadem University, 34684, Istanbul, Turkey;
f. Department of Pharmaceutical Sciences, University of Perugia, Perugia, 06123, Italy;
g. MAGI’S LAB, Rovereto (TN), Trentino, 38068, Italy

Received Date: Mar. 06, 2021
Accepted Date: Sep. 13, 2021
Rev Recd Date: Sep. 08, 2021
Available Online: Jan. 12, 2022
Publish Date: Dec. 15, 2021

Abstract

Abstract

The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.
- COVID-19 vaccine,
- Vaccine development platform,
- Coronavirus outbreak,
- SARS-CoV-2 variants,
- Treatment

FullText(HTML)

References(58)

References

H. Esakandari, M. Nabi-Afjadi, J. Fakkari-Afjadi, et al., A comprehensive review of COVID-19 characteristics, Biol. Proced. Online. 22 (2020), 19

M. Cascella, M. Rajnik, A. Aleem, et al., Features, Evaluation, and Treatment of Coronavirus (COVID-19), http://www.ncbi.nlm.nih.gov/pubmed/32150360. (accessed on 10 June, 2021)

A.K. Kiani, K. Dhuli, K. Anpilogov, et al., Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19, Acta Biomed. 91 (2020), e2020008

F. Bilgili, M. Dundar, S. Kuşkaya, et al., The age structure, stringency policy, income, and spread of coronavirus disease 2019: evidence from 209 countries, Front. Psychol. 11 (2021), 632192.

M. Dundar, A.S. Uzak, Y. Karabulut, Healthcare in overview of Turkey, EPMA J. 1 (2010) 587-594

I. Murrell, D. Forde, W. Zelek, et al., Temporal development and neutralising potential of antibodies against SARS-cov-2 in hospitalised COVID-19 patients: An observational cohort study, PLoS One. 16 (2021), e0245382

W. Li, F.J.M. van Kuppeveld, Q. He, et al., Cellular entry of the porcine epidemic diarrhea virus, Virus Res. 226 (2016) 117-127

Y.C. Liu, R.L. Kuo, S.R. Shih, COVID-19: The first documented coronavirus pandemic in history, Biomed. J. 43 (2020) 328-333

S.P. Kaur, V. Gupta, COVID-19 Vaccine: A comprehensive status report, Virus Res. 288 (2020), 198114

Y. Finkel, O. Mizrahi, A. Nachshon, et al., The coding capacity of SARS-CoV-2, Nature. 589 (2021) 125-130

A. Wu, Y. Peng, B. Huang, et al., Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China, Cell Host Microbe. 27 (2020) 325-328

E. Margolin, W.A. Burgers, E.D. Sturrock, et al., Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa, Nat. Rev. Microbiol. 18 (2020) 690-704

A.A. Rabaan, S.H. Al-Ahmed, R. Sah, et al., Recent advances in vaccine and immunotherapy for COVID-19, Hum. Vaccines Immunother. 16 (2020) 3011-3022

S.A. Mat Jusoh, P. Foroozandeh, Y.F. Lee, et al., COVID-19 Mini-Review: D614G Mutation as an Independent Risk-Factor to the Expression of ACE2 and DPP4 Associated Increased Severity in COVID-19, Sains Malays. 50 (2021) 1175-1186

M.P. Jogalekar, A. Veerabathini, P. Gangadaran, Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions, Exp. Biol. Med. 245 (2020) 964-969

S. Paolacci, M.R. Ceccarini, M. Codini, et al., Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis, Acta Biomed. 91 (2020), e2020009

M. Kandeel, A. Ibrahim, M. Fayez, et al., From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes, J. Med. Virol. 92 (2020) 660-666

W. Wang, J. Tang, F. Wei, Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China, J. Med. Virol. 92 (2020) 441-447

R. Lu, X. Zhao, J. Li, et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet. 395 (2020) 565-574

M. Gioia, C. Ciaccio, P. Calligari, et al., Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches, Biochem. Pharmacol. 182 (2020), 114225

F. Bruschi, M. Dundar, P.B. Gahan, et al., Biotechnology worldwide and the “European Biotechnology Thematic Network” Association (EBTNA), Curr. Opin. Biotechnol. 22 (2011) S7-S14

K.M.A. Gartland, F. Bruschi, M. Dundar, et al., Progress towards the “Golden Age” of biotechnology, Curr. Opin. Biotechnol. 24 (2013) S6-S13

T. Dallavilla, M. Bertelli, A. Morresi, et al., Bioinformatic analysis indicates that SARS-CoV-2 is unrelated to known artificial coronaviruses, Eur. Rev. Med. Pharmacol. Sci. 24 (2020) 4558-4564

M. Dettenhofer, M. Ondrejovic, A. Slavica, et al., Current state and prospects of biotechnology in Central and Eastern European countries. Part II: new and preaccession EU countries (CRO, RO, B&H, SRB), Crit. Rev. Biotechnol. 39 (2019) 137-155

M. Dettenhofer, M. Ondrejovic, V. Vasary, et al., Current state and prospects of biotechnology in Central and Eastern European countries. Part I: Visegrad countries (CZ, H, PL, SK), Crit. Rev. Biotechnol. 39 (2019) 114-136

M. Dundar, S. Prakash, R. Lal, et al., Future Biotechnology, EuroBiotech J. 3 (2019) 53-56

V. Precone, M. Dundar, T. Beccari, et al., Quality assurance of genetic laboratories and the EBTNA practice certification, a simple standardization assurance system for a laboratory network, EuroBiotech J. 2 (2018) 215-222

K.A. Hanley, The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine, Evol. Educ. Outreach. 4 (2011) 635-643

World Health Organization, COVID-19 vaccine tracker and landscape, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. (accessed on 27 August, 2021)

N.C. Kyriakidis, A. Lopez-Cortes, E.V. Gonzalez, et al., SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates, Npj Vaccines. 6 (2021), 28

Y. Der Li, W.Y. Chi, J.H. Su, et al., Coronavirus vaccine development: from SARS and MERS to COVID-19, J. Biomed. Sci. 27 (2020), 104

N. Wang, J. Shang, S. Jiang, et al., Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses, Front. Microbiol. 11 (2020), 298

L. Dai, G.F. Gao, Viral targets for vaccines against COVID-19, Nat. Rev. Immunol. 21 (2021) 73-82

S.M. Vrba, N.M. Kirk, M.E. Brisse, et al., Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats, Vaccines. 8 (2020), 680

W. Akahata, Z.Y. Yang, H. Andersen, et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection, Nat. Med. 16 (2010) 334-338

M.M. Silveira, G.M.S.G. Moreira, M. Mendonça, DNA vaccines against COVID-19: perspectives and challenges, Life Sci.. 267 (2021), 118919.

J.B. Alarcon, G.W. Waine, D.P. McManus, DNA vaccines: Technology and application as anti-parasite and anti-microbial agents, Adv. Parasitol. 42 (1999) 343-410

H.L. Robinson, T.M. Pertmer, DNA vaccines for viral infections: Basic studies and applications, Adv. Virus Res. 55 (2000), 1-74

P. Tulay, M.C. Ergoren, M. Dundar, COVID-19 vaccines: Where do we stand?, EuroBiotech J. 5 (2021) 4-7

M. Bertelli, S. Paolacci, T. Beccari, et al., Diagnostic and therapeutic implements based on advanced biotechnology should be available in low-income countries, Acta Biomed. 90 (2019) 5-6

J.M. Chen, Live unattenuated vaccines for controlling viral diseases, including COVID-19, J. Med. Virol. 93 (2021) 1943-1949

T. Kirby, New variant of SARS-CoV-2 in UK causes surge of COVID-19, Lancet. Respir. Med. 9 (2021), e20-e21

J. Singh, N.Z. Ehtesham, S.A. Rahman, et al., Structure-function investigation of a new VUI-202012/01 SARS-CoV-2 variant, BioRxiv. (2021), https://www.biorxiv.org/content/10.1101/2021.01.01.425028v1. (accessed on 31 May, 2021)

World Health Organization, SARS-CoV-2 Variants, https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/. (accessed on 3 June, 2021)

H. Tegally, E. Wilkinson, M. Giovanetti, et al., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa, MedRxiv. (2020), https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1. (accessed on 31 May, 2021)

N.R. Faria, I.M. Claro, D. Candido, et al., Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings, Virological.Org. (2021), https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586. (accessed on 31 May, 2021)

W. Zhang, B.D. Davis, S.S. Chen, et al., Emergence of a Novel SARS-CoV-2 Variant in Southern California, JAMA - J. Am. Med. Assoc. 325 (2021) 1324-1326

Public Health England, SARS-CoV-2 variants of concern and variants under investigation in England, Sage. (2021), https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201. (accessed on 6 September, 2021)

K.A. Twohig, T. Nyberg, A. Zaidi, et al., Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study, Lancet Infect Dis. (2021), https://www.sciencedirect.com/science/article/pii/S1473309921004758?via%3Dihub. (accessed on 6 September, 2021)

M.C. Ergoren, P. Tulay, M. Dundar, Are new genome variants detected in SARS-CoV-2 expected considering population dynamics in viruses?, EuroBiotech J. 5 (2021) 1-3

L. Guruprasad, Human SARS CoV-2 spik e protein mutations, Proteins Struct. Funct. Bioinforma. 89 (2021) 569-576

B. Korber, W.M. Fischer, S. Gnanakaran, et al., Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell. 182 (2020) 812-827.e19

European Centre for Disease Prevention and Control, SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update, Risk assessment. (2021), https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021. (accessed on 3 June, 2021)

C.K. Wibmer, F. Ayres, T. Hermanus, et al., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma, Nat. Med. 27 (2021) 622-625

World Health Organization, WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int. (accessed on 3 June, 2021)

J. Wise, Covid-19: New coronavirus variant is identified in UK, BMJ. 371 (2020), m4857

COVID-19 (SARS-CoV-2): information about the new virus variant, https://www.gov.uk/government/news/covid-19-sars-cov-2-information-about-the-new-virus-variant. (accessed on 3 June, 2021)

University of Washignton, New COVID-19 In-Depth Report: Summary of SARS-CoV-2 Novel Variants, https://globalhealth.washington.edu/news/2021/02/08/new-covid-19-literature-situation-report-summary-sars-cov-2-novel-variants. (accessed on 3 June, 2021)

Relative Articles

Supplements(0)

Cited By

Proportional views